The evidence that protein-coding genes represent less than 2% of all human genome, and that more than 90% of it is actively transcribed, changed the shared view that RNA is a bridge between DNA sequences and proteins. The introduction of RNA-Sequencing technology and the parallel expansion of computational biology revealed that thousands of sites produce non-coding transcripts. These molecules, collectively known as non-coding RNAs are key players in transcriptional and post-transcriptional regulation and in chromatin organization. Their altered expression is increasingly associated with pathological conditions. This chapter provides an overview about innovative high-throughput sequencing technologies and computational pipelines to profile non-coding RNAs, focusing on those with a proven epigenetic role. We examine the intriguing network between epigenome and ncRNAs and how these interactions are disrupted in human disease, thereby representing new potential clinical biomarkers.
High-Throughput Analysis of Noncoding RNAs: Implications in Clinical Epigenetics, published in the Book "Epigenetic Biomarkers and Diagnostics", 1st Edition
Costa V;Matarazzo MR;Gagliardi M;Esposito R;Ciccodicola A
2015
Abstract
The evidence that protein-coding genes represent less than 2% of all human genome, and that more than 90% of it is actively transcribed, changed the shared view that RNA is a bridge between DNA sequences and proteins. The introduction of RNA-Sequencing technology and the parallel expansion of computational biology revealed that thousands of sites produce non-coding transcripts. These molecules, collectively known as non-coding RNAs are key players in transcriptional and post-transcriptional regulation and in chromatin organization. Their altered expression is increasingly associated with pathological conditions. This chapter provides an overview about innovative high-throughput sequencing technologies and computational pipelines to profile non-coding RNAs, focusing on those with a proven epigenetic role. We examine the intriguing network between epigenome and ncRNAs and how these interactions are disrupted in human disease, thereby representing new potential clinical biomarkers.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
